InMed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	3.25	4.94	4.6	4.14	1.09	-
Revenue Growth (YoY)	-34.06%	7.50%	11.18%	279.60%	-	-
Cost of Revenue	2.08	3.24	3.5	2.73	0.55	-
Gross Profit	1.16	1.71	1.1	1.4	0.54	-
Selling, General & Admin	7.15	6.56	5.8	5.85	6.87	4.48
Depreciation & Amortization Expenses	0.21	0.21	0.22	0.2	0.19	0.12
Research & Development	2.35	2.85	3.22	3.73	7.28	5.34
Other Operating Expenses	0.04	0.03	0.06	0.05	3.47	-
Total Operating Expenses	9.75	9.65	9.3	9.83	17.81	9.94
Operating Income	-8.58	-7.95	-8.2	-8.43	-17.26	-9.94
Interest Expense	-0.02	-0.37	-	-	-	-0.36
Other Non-Operating Income (Expense)	0.27	0.16	0.53	0.49	-1.34	0.1
Total Non-Operating Income (Expense)	0.25	-0.22	0.53	0.49	-1.34	-0.26
Pretax Income	-8.34	-8.16	-7.67	-7.93	-18.6	-10.2
Provision for Income Taxes	-	-	-0.01	-0.01	-	-
Net Income	-8.51	-8.16	-7.68	-7.95	-18.6	-10.2
Earnings From Discontinued Operations	-0.17	-	-	-	-	-
Net Income to Common	-8.51	-8.16	-7.68	-7.95	-18.6	-10.2
Shares Outstanding (Basic)	3	1	0	1	1	1
Shares Outstanding (Diluted)	3	1	0	1	1	1
Shares Change (YoY)	363.37%	156.13%	-32.05%	-	-	-89.26%
EPS (Basic)	-2.11	-8.36	-20.14	-3.25	-33.17	-37.96
EPS (Diluted)	-2.11	-8.36	-20.14	-3.25	-33.17	-37.96
Shares Outstanding	3.31	2	0.45	3.33	0.65	0.32
Free Cash Flow	-7.46	-7.77	-7	-7.45	-15.62	-9.79
Free Cash Flow Per Share	-2.22	-7.96	-18.36	-13.28	-27.86	-17.46
Gross Margin	35.87%	34.53%	23.94%	33.93%	49.89%	-
Operating Margin	-264.55%	-160.77%	-178.27%	-203.77%	-1584.71%	-
Profit Margin	-256.86%	-165.14%	-166.63%	-191.54%	-1707.32%	-
FCF Margin	-229.81%	-157.14%	-152.14%	-180.02%	-1434.03%	-
EBITDA	-8.01	-7.41	-7.59	-7.83	-16.75	-9.71
EBITDA Margin	-246.70%	-149.95%	-165.12%	-189.36%	-1537.73%	-
EBIT	-8.58	-7.95	-8.2	-8.43	-17.26	-9.94
EBIT Margin	-264.55%	-160.77%	-178.27%	-203.77%	-1584.71%	-
Effective Tax Rate	-	0.00%	0.09%	0.17%	0.00%	0.00%

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q